[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510571":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":28,"responsibleParty":47,"collaborators":7,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":7,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":7,"studyType":63,"phases":7,"briefSummary":64,"conditions":65,"keywords":74,"overallStatus":31,"whyStopped":7,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University Hospital Schleswig-Holstein","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Topical and systemic drugs","Recruitment and follow-up will be independent on the type of treatment",[14],{"name":15,"affiliation":5,"role":16},"Sascha Gerdes, MD","STUDY_DIRECTOR",[18,24],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},"Stephan Weidinger, MD","CONTACT","0049431500","21101","sweidinger@dermatology.uni-kiel.de",{"name":25,"role":20,"phone":21,"phoneExt":26,"email":27},"Stefanie Sievers","21102","ssievers@dermatology.uni-kiel.de",[29],{"facility":30,"status":31,"city":32,"state":7,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Department of Dermatology and Allergy, University Hospital Schleswig-Holstein","RECRUITING","Kiel","24105","Germany","DE",{"type":37,"coordinates":38},"Point",[39,40],10.13489,54.32133,{"lat":40,"lon":39},[43,44],{"name":25,"role":20,"phone":21,"phoneExt":26,"email":27},{"name":45,"role":20,"phone":21,"phoneExt":22,"email":46},"Jacline Wendler","jwendler@dermatology.uni-kiel.de",{"type":48,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Prof. Dr. Stephan Weidinger","100510571","determinants-of-chronic-inflammatory-skin-disease-trajectories-100510571",false,"NCT05928169","Determinants of Chronic Inflammatory Skin Disease Trajectories","Inclusion Criteria:\n\n* dermatologist-diagnosed inflammatory skin disease\n* informed consent\n\nExclusion Criteria:\n\n* subject and\u002For the legal guardians are not able to give written informed consent\n* pregnant and breastfeeding women\n* concurrent participation in a clinical trial\n* use of systemic immunosuppressive therapy or phototherapy during the last 4 weeks or receipt of biologics therapy (e.g. dupilumab, tralokinumab) within the last 3 months\n* treatment of the target skin areas with topical corticosteroids, calcineurin inhibitors or emollients 24 hours before sample collection",true,"ALL","0 Years","80 Years",{"count":61,"type":62},1000,"ESTIMATED","OBSERVATIONAL","Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation, clinical features and course are also largely unknown. There are currently no reliable markers that could predict or delineate patient subgroups to support patient management. The aim of this project is to identify clinical and molecular factors that correlate with disease, disease subtypes and progression through in-depth long-term clinical characterization of patients with chronic inflammatory skin diseases and examination of individual biomaterials.",[66,67,68,69,70,71,72,73],"Atopic Dermatitis","Psoriasis","Lichen Planus","Alopecia Areata","Hidradenitis Suppurativa","Prurigo Nodularis","Cutaneous Lupus","Rosacea",[75],"Inflammatory Skin Diseases","2025-07-17",{"date":78,"type":79},"2025-07-22","ACTUAL",{"date":81,"type":79},"2023-05-01",{"date":83,"type":62},"2032-12-31",{"name":5,"class":6},1]